Flurizan Reverses Disease Course and Improves Cognitive Function in Follow-on

SALT LAKE CITY, Nov. 15 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - News; http://www.myriad.com/) announced today that an analysis of data from its Phase 2 follow-on study of Flurizan(TM) in patients with mild Alzheimer's disease showed that study participants improved as a group, regaining cognitive ability from months 12 through 18. Results of the 6-month follow-on study were presented today at the Neuroscience 2005 meeting in Washington, D.C., by Sandra E. Black, M.D., Professor of Neurology at the University of Toronto and lead investigator in Canada for the Phase 2 trial of Flurizan in patients with Alzheimer's disease.